Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR201820192020202120222023
Revenues<1m<1m<1m<1m<1m<1m
% growth-4559 %586 %(78 %)40 %43 %
EBITDA(<1m)(<1m)(<1m)(<1m)--
% EBITDA margin(966 %)(38 %)(25 %)(342 %)--
Profit(<1m)(<1m)(<1m)(<1m)--
% profit margin(727 %)(30 %)(20 %)(286 %)--
  • Edit
DateInvestorsAmountRound
-

N/A

-

€56.0k

Grant
*

N/A

Spinout

€40.0k

Grant
*

€200k

Seed

€35.0k

Grant
N/A

$497k

Convertible

€334k

Angel

€2.4m

Grant
*

€5.4m

Seed
Total FundingCAD13.4m

Recent News about ADmit Therapeutics

Edit
More about ADmit Therapeutics
Edit

Developer of a medical diagnostic test intended to come up with early detection for Alzheimer's disease. The company's diagnostic test is based on an epigenetic analysis in blood samples that covers methylcytosines with next-generation sequencing, enabling medical practitioners to identify Alzheimer's and accelerate the identification of curative drugs in a simplified way.

Keywords: Pharmaceuticals and Biotechnology, Alzheimer Detection, Alzheimer Diagnostics, Alzheimer'S Disease Diagnostics, Diagnostic Test Systems, Diagnostic Testing, Disease Detection.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.